Janet Lau

486 total citations
8 papers, 367 citations indexed

About

Janet Lau is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Janet Lau has authored 8 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Neurology. Recurrent topics in Janet Lau's work include HER2/EGFR in Cancer Research (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Cancer therapeutics and mechanisms (1 paper). Janet Lau is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Cancer therapeutics and mechanisms (1 paper). Janet Lau collaborates with scholars based in United States, France and United Kingdom. Janet Lau's co-authors include Jeanne Cheung, Jacqueline McBride, Maike Schmidt, Jane L. Grogan, Laura Sanders, Steve Lianoglou, Jeong Kim, Benjamin Haley, Klára Tótpál and Robert L. Yauch and has published in prestigious journals such as Nature Communications, PLoS ONE and Cancer Research.

In The Last Decade

Janet Lau

7 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet Lau United States 5 259 199 76 37 35 8 367
Philipp Knopf Germany 5 286 1.1× 201 1.0× 55 0.7× 41 1.1× 36 1.0× 10 357
Francesca Amicarella Switzerland 8 273 1.1× 263 1.3× 86 1.1× 43 1.2× 36 1.0× 10 436
Kristan Guenterberg United States 8 261 1.0× 310 1.6× 112 1.5× 24 0.6× 16 0.5× 9 450
Sarah Greene United States 5 370 1.4× 393 2.0× 81 1.1× 40 1.1× 34 1.0× 5 516
Sara Fritzell Sweden 9 174 0.7× 182 0.9× 55 0.7× 21 0.6× 25 0.7× 16 301
Ahmed Raji Iraq 3 204 0.8× 132 0.7× 97 1.3× 68 1.8× 31 0.9× 8 319
Wenjing Yang United States 9 189 0.7× 229 1.2× 68 0.9× 28 0.8× 26 0.7× 13 318
Shujun Xing China 6 190 0.7× 116 0.6× 92 1.2× 41 1.1× 25 0.7× 11 282
Chris Silvin United States 4 290 1.1× 323 1.6× 71 0.9× 26 0.7× 30 0.9× 4 405
Stephanie O. Dudzinski United States 5 126 0.5× 132 0.7× 68 0.9× 46 1.2× 33 0.9× 12 268

Countries citing papers authored by Janet Lau

Since Specialization
Citations

This map shows the geographic impact of Janet Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Lau more than expected).

Fields of papers citing papers by Janet Lau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Lau. The network helps show where Janet Lau may publish in the future.

Co-authorship network of co-authors of Janet Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Lau. A scholar is included among the top collaborators of Janet Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Lau. Janet Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Ko, Andrew H., Kyu‐pyo Kim, Jens T. Siveke, et al.. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist. 28(6). 553–e472. 37 indexed citations
2.
Li, Wěi, Qifeng Qiu, Kerstin W. Sinkevicius, et al.. (2019). Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters. 10(10). 1386–1392. 30 indexed citations
3.
Lau, Janet, Kerstin W. Sinkevicius, Stuart W. Hicks, et al.. (2019). Abstract 538: LC-MS based catabolite identification study of an ADC with DM21-C, a novel maytansinoid linker-payload. Cancer Research. 79(13_Supplement). 538–538. 1 indexed citations
4.
Lau, Janet, Jeanne Cheung, Armando Navarro, et al.. (2017). Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nature Communications. 8(1). 14572–14572. 270 indexed citations
5.
Lau, Janet, Qiang Zhou, Susan Sutton, et al.. (2014). Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice. PLoS ONE. 9(1). e84900–e84900. 9 indexed citations
6.
Lau, Janet, Bing Guan, Thomas Ryll, et al.. (2014). High‐throughput ion exchange purification of positively charged recombinant protein in the presence of negatively charged dextran sulfate. Biotechnology Progress. 30(2). 516–520. 4 indexed citations
7.
Lau, Janet, Deborah Knee, Christophe Filippi, et al.. (2013). IL-2 Immunotherapy Reveals Potential for Innate Beta Cell Regeneration in the Non-Obese Diabetic Mouse Model of Autoimmune Diabetes. PLoS ONE. 8(10). e78483–e78483. 14 indexed citations
8.
Lau, Janet, et al.. (1994). Technician assistance in switching patients from injectable to oral therapy. American Journal of Health-System Pharmacy. 51(3). 384–386. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026